The FDA has approved Apidra SoloSTAR (insulin glulisine[rDNA origin] injection, from sanofi-aventis), a prefilled disposable pencontaining Apidra. Apidra SoloSTAR makes administration of insulin ...

BRIDGEWATER, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) SoloSTAR(R ...

Sanofi (Euronext: SAN; NYSE: SNY) announced today that it received FDA approval for its Toujeo Max SoloStar insulin pen, the highest capacity long-acting insulin pen that will be available on the ...

The Lantus SoloStar insulin pen will be affected by the new labeling requirements. The FDA is taking action to ensure that multidose insulin pens do not spread diseases by requiring the injectable ...

Feb. 27 -- THURSDAY, Feb. 26 (HealthDay News) -- Sanofi-Aventis's Apidra (insulin glulisine) Solostar injection pen has been approved to treat diabetes, the company said Thursday in a news release.

∙ As a first result of the exclusive negotiations initiated in July, the two companies sign a global distribution agreement ∙ After an initial payment of €4 million, BIOCORP receives a new payment of ...

Medtronic's launch of a new version of its smart insulin pen with integrated continuous glucose monitoring (CGM) is the first such "connected" device for use by people with diabetes who use multiple ...

Lantus ® (“Lantus”) is Sanofi’s insulin glargine product. The U.S. Food and Drug Administration (FDA) first approved Lantus in 2000 as a sterile solution of insulin glargine for use as an injection.

A longer-acting version of the world's best-selling diabetes drug is now available in the U.K. Sanofi ($SNY) announced the availability of the long-acting basal ...

Apidra SoloSTAR (insulin glulisine [rDNA origin] injection, from sanofi-aventis), a prefilled disposable pen containing Apidra, is now available. Apidra SoloSTAR makes administration of insulin more ...